Since proliferation of the progenitor exhausted CD8+ T cells in response to TCR stimulation and PD-1 blockade progressively leads to their conversion to terminally exhausted phenotype2, approaches to maintain or expand the progenitor subset of exhausted CD8+ T cells may help sustain anti-tumor response induced by anti-PD-1 therapy. This evidence concerns the gene CD8A and neoplasm.